S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)

Novavax (NVAX) Earnings Date, Estimates & Call Transcripts

$4.94
+0.53 (+12.02%)
(As of 02/29/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 28)
-$1.44 Missed By -$0.95
Consensus EPS
(Feb. 28)
-$0.49
Skip Charts & View Estimated and Actual Earnings Data

NVAX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NVAX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Novavax Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($0.64)($0.09)($0.37) 
Q2 20242($1.38)($1.36)($1.37) 
Q3 20242($0.74)($0.64)($0.69) 
Q4 20242$0.72$1.69$1.21 
FY 20248($2.04)($0.40)($1.22) 
Q1 20251($0.30)($0.30)($0.30) 
Q2 20251($0.31)($0.31)($0.31) 

NVAX Earnings Date and Information

Novavax last issued its quarterly earnings results on February 28th, 2024. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.95. The company earned $291.34 million during the quarter, compared to analysts' expectations of $310.96 million. Its quarterly revenue was down 18.5% compared to the same quarter last year. Novavax has generated ($6.37) earnings per share over the last year (($6.37) diluted earnings per share). Earnings for Novavax are expected to grow in the coming year, from ($4.31) to ($0.26) per share. Novavax has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Novavax Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
2/28/2024Q4 2023($0.49)($1.44)($0.95)($1.44)$310.96 million$291.34 million      
11/9/2023Q3 2023($1.82)($1.26)+$0.56($1.26)$171.04 million$187.00 million      
8/8/2023Q2 2023($1.24)$0.58+$1.82$0.58$264.16 million$424.40 million      
5/9/2023Q1 2023($3.38)($3.41)($0.03)($3.41)$94.52 million$81.00 million      
2/28/2023Q4 2022($0.92)($2.28)($1.36)($2.28)$383.14 million$357.40 million    
11/8/2022Q3 2022$2.21($2.15)($4.36)($2.15)$555.50 million$734.58 million      
8/8/2022Q2 2022$5.51($6.53)($12.04)($6.53)$1.02 billion$186.00 million    
5/9/2022Q1 2022$3.33$2.56($0.77)$2.56$845.20 million$703.97 million    
2/28/2022Q4 2021($1.43)($11.18)($9.75)($11.18)$331.79 million$222.20 million    
11/4/2021Q3 2021($4.04)($4.31)($0.27)($4.31)$347.34 million$178.80 million    
8/5/2021Q2 2021($3.63)($4.75)($1.12)($4.75)$370.80 million$298.02 million    
5/10/2021Q1 2021($2.65)($3.05)($0.40)($3.05)$233.90 million$447.00 million  
3/1/2021Q4 2020($1.53)($2.70)($1.17)($2.70)$202.44 million$279.66 million  












Novavax Earnings - Frequently Asked Questions

When is Novavax's earnings date?

Novavax has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on NVAX's earnings history.

Did Novavax beat their earnings estimates last quarter?

In the previous quarter, Novavax (NASDAQ:NVAX) missed the analysts' consensus estimate of ($0.49) by $0.95 with a reported earnings per share (EPS) of ($1.44). Learn more on analysts' earnings estimate vs. NVAX's actual earnings.

How can I listen to Novavax's earnings conference call?

The conference call for Novavax's latest earnings report can be listened to online. Listen to Conference Call

How can I read Novavax's conference call transcript?

The conference call transcript for Novavax's latest earnings report can be read online. Read Transcript

How can I view Novavax's earnings report?

Novavax's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Novavax generate each year?

Novavax (NASDAQ:NVAX) has a recorded annual revenue of $1.98 billion.

How much profit does Novavax generate each year?

Novavax (NASDAQ:NVAX) has a recorded net income of -$657.94 million. NVAX has generated -$6.37 earnings per share over the last four quarters.

What is Novavax's EPS forecast for next year?

Novavax's earnings are expected to grow from ($4.31) per share to ($0.26) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:NVAX) was last updated on 2/29/2024 by MarketBeat.com Staff